All AbMole products are for research use only, cannot be used for human consumption.
VU0357121 does not have PAM activity at other mGluR subtypes, neither binds at the MPEP allosteric site of mGlu5, thus does not possess mGlu5 NAM activity. The A809V/rmGlu5 mutation inhibited the ability of VU0357121 to shift the glutamate concentration−response curve, whereas the response to VU0357121 is not altered by the F585I/rmGlu5 mutation. VU0357121 show weaker cooperativity in the Ca2+ mobilization assay in the low-expressing HEK293A-mGlu5 cell line.
Molecular Weight | 305.32 |
Formula | C17H17F2NO2 |
CAS Number | 433967-28-3 |
Solubility (25°C) | DMSO 50 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Christine E Wells, et al. Déjà vu experiences in anxiety
[2] Marija Bošnjak Pašić, et al. Many Faces of Déjà Vu: a Narrative Review
[3] Maarten P Bebelman, et al. Biogenesis and function of extracellular vesicles in cancer
Related GluR Products |
---|
VU0650786
VU0650786 is a potent and selective CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 (mGlu3 NAM), with an IC50 of 392 nM. |
NS-102
NS-102 is a selective kainate (GluK2) receptor antagonist. |
VU0424465
VU0424465 is a potent and partial PAM (positive allosteric modulator)-agonist for mGlu5 mediated iCa2+ mobilization. |
ATPA
ATPA is a selective glutamate receptor GluR5 activator with EC50s of 0.66, 9.5, 1.4, 23, 32, 18, and 14 μM for GluR5wt, GluR5(S741M), GluR5(S721T), GluR5(S721T, S741M), GluR5(S741A), GluR5(S741L), and GluR5(S741V), respectively. |
(R)-CPP
(R)-CPP is a highly potent NMDA receptor antagonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.